ClinicalTrials.gg
TerminatedNCT04009681HAMMERUpdated Dec 15, 2025

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

A Phase 1/2 interventional study of THOR-707 and Checkpoint inhibitor in Metastasis, sponsored by Synthorx, Inc, a Sanofi company. Terminated at 24 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Synthorx, Inc, a Sanofi company (part of Sanofi) · Phase 1/2, Interventional, and Treatment

How we know · 9 judgments

Why this study was terminated
The study was terminated as per Sponsor decision. The decision was not related to any safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
175
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Neoplasm Metastasis by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Neoplasm Metastasis · Sanofi.

Enrollment
12th of 31
175 · median 98
Started
2019
with 2 others
Phase 1/2
5 of 31
1 open now
Registered
29th of 31
by date

Among the 31 studies in Neoplasm Metastasis by Sanofi, this one is the 12th largest by enrollment, is one of 3 that started in 2019, is one of 5 in phase 1/2, and was the 29th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

1 of the 31 studies in Neoplasm Metastasis by Sanofi is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Neoplasm Metastasis by Sanofi, or all of them as a file.
02

Study summary

Primary Objectives:

  • Evaluate the safety and tolerability of THOR-707 as a single agent and as a combination therapy (identify Dose Limiting Toxcitiy (DLTs) in Cohorts A, B, C, D, and G, and adverse events (AEs)/serious adverse event (SAE) profile in Cohorts A, B, C, D, E, F, and G)
  • Define the Maximium Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of THOR-707 as a single agent and as a combination therapy (Cohorts A, B, C, D, and G)
  • Evaluate preliminary anti-tumor activity of THOR-707 as a single agent by determination of the objective response rate (ORR) defined according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Cohort H only)

Secondary Objectives:

  • Evaluate preliminary anti-tumor activity of THOR-707 as a single agent and as a combination therapy by determination of the objective response rate (ORR) defined according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Cohorts A, B, C, D, E, F, and G)
  • Determine time to response (TTR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and clinical benefit rate (CBR) of THOR-707 as a single agent and as a combination therapy
  • Evaluate the safety and tolerability of THOR-707 monotherapy QW/Q2W (AE/serious adverse event [SAE] profile) (Cohort H only).
Read the detailed description

The study duration per participant is approximately 24 months (inclusive of follow-up). Cohorts A, B, C, and D have been completed.

03

Conditions studied

  • Metastasis

Keywords

  • Synthorx
  • THOR-707
  • THOR 707
  • Interleukin 2
  • Interleukin-2
  • IL2
  • oncology
  • immuno-oncology
  • immunotherapy
  • IL-2
  • SAR444245
  • Sanofi
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • per v1.1. For Cohort G participants must have at least 1 measurable lesion, and for Part 3 (Cohorts E, F and H) participants must have at least 2 measurable lesions to safely perform mandatory pre \& on-treatment .
  • greater than or equal to 12 weeks.
  • For Part 2 exclusively: While it is highly preferred to enroll subjects who are naïve to inhibitors into a Part 2 dose escalation cohort, this is not an enrollment requirement. However, subjects who enroll into a Part 2 safety expansion cohort must be naïve to PD-1 inhibitors. If such subject is unable to meet this requirement but otherwise remains a good candidate for study enrollment, the Investigator should discuss with the Sponsor whether the subject may be enrolled.
  • (ECOG) performance status of 0 or 1.
  • Adequate cardiovascular, hematological, liver, and renal function.
  • or cytologically confirmed diagnosis of advanced and/or solid tumors with at least one tumor lesion with location accessible to safely biopsy per clinical judgment of the Investigator.

    • Caution: Cohort D only patients with KRAS mutant colon cancer have not typically benefitted from the addition of cetuximab in earlier .
    • Caution: Cohorts E \& F enrollment will include only patients with tumors for which anti-PD(L)1 as single agent or in combination treatments are approved.
    • Caution: For Cohort H, the participant must have received at least one prior line of therapy for metastatic melanoma and/or does not have any standard of care (SoC) treatment option or participant declines or is intolerant to be treated with SoC treatment.
  • Subjects with advanced or metastatic solid tumors who have refused SoC; or for whom no reasonable SoC exists that would confer clinical benefit; or for whom standard therapy is intolerable, not effective, or not accessible.
  • Prior anti-cancer therapy is allowed as long as any treatment related toxicity is resolved to an appropriate level.
  • Females of and men who are not surgically sterile must agree to use medically-accepted method of during the study and for at least7 days (for Cohorts A, B, G and H), at least 2 months (for Cohort D), or at least 4 months (for Cohorts C, E and F) for females, and for at least 3 days for males [corresponding to the time needed to eliminate study intervention] after the last dose of study intervention.
  • [Females] Negative serum pregnancy test within 7 days prior to initiating study treatment in premenopausal women and women less than 12 months after menopause.
  • [Males] Agreement to refrain from donating or banking sperm during the treatment period and for at least 3 days after last dose of study treatment.
  • In Spain, Chile, and Argentina: Only cohorts G and H will be open to enrollment.

Key Exclusion Criteria:

  • Radiotherapy ≤ 14 days prior to first dose of study drug (palliative radiation or stereotactic radiosurgery within 7 days prior to start of study treatment).
  • Treated with systemic anti-cancer therapy or an agent within 2 weeks prior to start of study drug treatment (within 4 weeks for immunotherapy and tyrosine kinase inhibitor therapy).
  • Subjects who experienced Grade 3 or higher immune-related toxicity from prior immuno-oncology therapy.
  • Major surgery ≤ 30 days prior to first dose of study drug, or has not recovered to at least Grade 1 from adverse effects from such procedure, or anticipation of the need for major surgery during study treatment.
  • Active disease requiring systemic treatment within the past 3 months or have a documented history of clinically severe autoimmune disease that requires systemic or agents.
  • Primary central nervous system (CNS) disease or ; known unless treated, are asymptomatic, are without evidence of radiological progression for at least 8 weeks, and have had no requirement for steroids or enzyme inducing anticonvulsants in the last 14 days prior to Screening.
  • Abnormal pulmonary function within the previous 6 months, including pneumonitis, active pneumonitis, interstitial lung disease requiring the use of steroids, idiopathic pulmonary fibrosis, confirmed pleural effusion, severe dyspnea at rest or requiring supplementary oxygen therapy.
  • Parenteral antibiotics within 14 days of the first dose of study drug.
  • History of allogenic or solid organ transplant.
  • Uncontrolled diabetes mellitus or other uncontrolled immune-related endocrinopathies in the opinion of the Investigator.
  • Known (HIV) infection or active infection with .
  • For known uncontrolled virus (HBV) infection:

    i. Anti-HBV therapy started before initiation of IMP and HBV viral load \<2000 IU/mL (104 copies/mL) are eligible. The anti-HBV therapy should continue throughout the treatment period. ii. Positive anti-HBc, positive anti HBs, negative HBsAg, and HBV virus load without HBV therapy are eligible.

  • Received a live-virus vaccination ≤14 days prior to first dose of study drug. Seasonal flu and other inactivated vaccines that do not contain live virus are permitted.
  • bleeding within 2 weeks prior to initial THOR-707 dose (e.g., gastrointestinal bleeding, intracranial hemorrhage).
  • Prior diagnosis of deep vein thrombosis or pulmonary embolism within 3 months.
  • Severe or unstable cardiac condition within 6 months prior to starting study treatment, such as congestive heart failure ( Class III or IV), cardiac bypass surgery or coronary artery stent placement, angioplasty, cardiac below the lower limit of normal, unstable angina, medically uncontrolled hypertension (e.g. ≥160 mm Hg systolic or ≥100 mm Hg diastolic), uncontrolled cardiac arrhythmia requiring medication (≥ grade 2, according to v5.0), or myocardial infarction.
  • History of non-pharmacologically induced prolonged interval determined using Fridericia's formula (QTcF) > 450 milliseconds (msec) in males or > 470 msec in females.
  • Known or to any components of THOR-707, PEG, pegylated drugs, and E. coli derived-protein, checkpoint inhibitor, or anti-EGFR antibody for applicable cohorts.
  • Active second , or history of previous malignancy that would impact the assessment of any study endpoints. Subjects with non-melanomatous skin cancer or cervical cancer that has been curatively surgically resected are eligible.
  • Any serious medical condition (including pre-existing autoimmune disease or inflammatory disorder), laboratory abnormality, psychiatric condition, or any other significant or unstable concurrent medical illness that in the opinion of the Investigator would preclude protocol therapy or would make the subject inappropriate for the study.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through for at least 7 days (for Cohorts A, B, G, and H), at least 2 months (for Cohort D), or at least 4 months (for Cohorts C, E, and F) for females and for at least 3 days for males [corresponding to the time needed to eliminate study intervention] after the last dose of study intervention.
  • Concurrent therapy with any other investigational agent, vaccine, or device. Concomitant participation in observational studies is acceptable after Sponsor approval.
  • For Cohort D only: patients with symptomatic keratitis and/or symptomatic dry eye should be excluded from enrollment. Patients who wear contact lenses should be advised to avoid contact lenses use as it could result in keratitis.
  • Subjects with baseline oxygen saturation \<92% are not eligible for enrollment.
  • For participants in Cohort H: Participants with uveal or ocular or desmoplastic metastatic melanoma.

The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.

Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Cohort A-THOR-707 Q2W Monotherapy (Dose Escalation)

    Subjects with advanced or metastatic solid tumors will receive THOR-707 in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W) until unacceptable toxicity, disease progression, or withdrawal of consent.

    Drug: THOR-707

  • Experimental
    Cohort B-THOR-707 Q3W Monotherapy (Dose Escalation)

    Subjects with advanced or metastatic solid tumors will receive THOR-707 in sequential ascending doses as a monotherapy via IV administration every 3 weeks (Q3W) until unacceptable toxicity, disease progression, or withdrawal of consent.

    Drug: THOR-707

  • Experimental
    Cohort C-THOR-707 Q3W with checkpoint inhibitor (Dose Escalation)

    Subjects with advanced or metastatic solid tumors will receive THOR-707 Q3W in sequential ascending doses in combination with a checkpoint inhibitor Q3W or every 6 weeks (Q6W) via IV administration until unacceptable toxicity, disease progression, or withdrawal of consent.

    Drug: THOR-707 · Drug: Checkpoint inhibitor

  • Experimental
    Cohort D-THOR-707 Q3W with anti-EGFR antibody (Dose Escalation)

    Subjects with advanced or metastatic solid tumors will receive THOR-707 Q3W in sequential ascending doses in combination with an anti-EGFR antibody weekly dosing (QW) via IV administration until unacceptable toxicity, disease progression, or withdrawal of consent.

    Drug: THOR-707 · Drug: anti-EGFR antibody

  • Experimental
    Cohort E-THOR-707 Q2W with checkpoint inhibitor (Dose Expansion)

    Subjects with advanced or metastatic solid tumors will receiveTHOR-707 Q2W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W; it will consist of one 8-week cycle of THOR-707 monotherapy on Cycle 1 Day 1 followed by THOR-707 Q2W + checkpoint inhibitor Q6W starting at Cycle 1 Day 15. Subsequently treatment will consist of repeated 6-week cycles with combination therapy.

    Drug: THOR-707 · Drug: Checkpoint inhibitor

  • Experimental
    Cohort F-THOR-707 Q3W with checkpoint inhibitor (Dose Expansion)

    Subjects with advanced or metastatic solid tumors will receive THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy on Cycle 1 Day 1 followed by THOR-707 Q3W + checkpoint inhibitor at Cycle 1 Day 22. Subsequently treatment will consist of repeated 6-weeks cycles with combination therapy.

    Drug: THOR-707 · Drug: Checkpoint inhibitor

  • Experimental
    Cohort G Monotherapy QW/Q2W (Dose Escalation)

    Subjects with advanced or metastatic solid tumors will receive THOR707 monotherapy QW for 6 weeks (induction period), and then every Q2W (maintenance period), which is referred as QW/Q2W thereafter, until unacceptable toxicity, disease progression, or withdrawal of consent.

    Drug: THOR-707

  • Experimental
    Cohort H Monotherapy QW/Q2W (Dose Expansion)

    Subjects with late-line metastatic melanoma will receive THOR707 monotherapy at RP2D for Cohort G. Cycle 1 will consist of THOR-707 QW for 6 weeks; Cycle 2 and beyond will consist of THOR-707 Q2W.

    Drug: THOR-707

Interventions

  • DrugPegenzileukinStudies of PegenzileukinPegenzileukin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration

    Also known as: SAR444245, Pegenzileukin

  • DrugPembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pharmaceutical form: solution for IV administration; Route of administration: IV administration

    Also known as: pembrolizumab

  • DrugEGFR AntibodyStudies of EGFR AntibodyEGFR Antibody pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pharmaceutical form: solution for IV administration; Route of administration: IV administration

    Also known as: cetuximab

06

What researchers measure

Primary outcomes

  1. Rate of Dose-Limiting Toxicities (DLTs)- Cohorts A, B, C, and D

    Based on toxicities observed

    Time frame: Study Day 1 up to Day 29

  2. Maximum Tolerated Dose (MTD)- Cohorts A, B, C, and D

    Based on toxicities observed

    Time frame: Study Day 1 up to Day 29

  3. Recommended Phase 2 Dose (RP2D)- Cohorts A, B, C, and D

    Based on toxicities observed

    Time frame: Study Day 1 up to Day 29

  4. Number of participants with treatment emergent adverse events, serious adverse events, and laboratory abnormalities - Cohorts A, B, C, D, E, F, and G

    Safety will be assessed by monitoring adverse events, clinical laboratory evaluations, vital signs, and ECG parameters.

    Time frame: Study Day 1 up to approximately 24 months

  5. Rate of Dose-Limiting Toxicities (DLTs) -Cohort G

    Based on toxicities observed

    Time frame: Study Day 1 up to Day 42 (6 week-cycle)

  6. Recommended Phase 2 Dose (RP2D) of THOR-707- Cohort G

    Based on toxicities observed

    Time frame: Study Day 1 up to Day 42 (6 week-cycle)

  7. Maximum Tolerated Dose (MTD)- Cohort G

    Based on toxicities observed

    Time frame: Study Day 1 up to Day 42 (6 week-cycle)

  8. Objective Response Rate (ORR) according to RECIST version 1.1 -Cohort H

    ORR, defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥4 weeks after initial documentation of response.

    Time frame: Study Day 1 up to approximately 24 months

Secondary outcomes

  1. Objective Response Rate (ORR) according to RECIST version 1.1 Cohort A, B, C, D, E, F, and G)

    Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥4 weeks after initial documentation of response.

    Time frame: Study Day 1 up to approximately 24 months

  2. Duration of Response (DOR) according to RECIST version 1.1

    Defined as time from date of first objective response (either CR or PR) to first documentation of radiographic disease progression or death due to any cause, whichever occurs first.

    Time frame: Study Day 1 up to approximately 24 months

  3. Progression-Free Survival (PFS) according to RECIST version 1.1

    Defined as the time from first dose of THOR-707 to first documentation of radiographic disease progression or death due to any cause, whichever occurs first.

    Time frame: Study Day 1 until the date of first documented progression or date of death from any cause, assessed up to approximately 24 months

  4. Overall Survival according to RECIST version 1.1

    Defined as the time from first dose of THOR-707 to the date of death due to any cause.

    Time frame: Study Day 1 up to time of death, assessed up to approximately 24 months

  5. Time to Response (TTR) according to RECIST version 1.1

    Defined as the time from first dose of THOR-707 to first documentation of objective response (either CR or PR).

    Time frame: Study Day 1 up to approximately 24 months

  6. Disease Control Rate (DCR) according to RECIST version 1.1

    Defined as the proportion of subjects who have achieved confirmed CR, PR, or stable disease (SD) determined by Investigator per RECIST 1.1.

    Time frame: Study Day 1 up to approximately 24 months

  7. Clinical Benefit Rate (CBR)

    Defined as the proportion of participants with clinical benefit i.e., confirmed CR or PR as BOR (is defined as the best overall response observed from the date of first IMP until disease progression, death, cut-off date or initiation of subsequent anti-cancer therapy, whichever occurs first), or SD lasting at least 6 months.

    Time frame: Study Day 1 up to approximately 24 months

  8. Number of participants with treatment emergent adverse events, serious adverse events, laboratory abnormalities -Cohort H

    Safety will be assessed by monitoring adverse events, clinical laboratory evaluations, vital signs, and ECG parameters.

    Time frame: Study Day 1 up to approximately 24 months

07

Study locations

24 sites
  • Investigational Site Number-1008
    Scottsdale, Arizona 85250, United States
  • Investigational Site Number-1005
    Denver, Colorado 80218, United States
  • Investigational Site Number-1004
    Sarasota, Florida 34232, United States
  • Investigational Site Number-1003
    Nashville, Tennessee 37203, United States
  • Investigational Site Number-1007
    Dallas, Texas 75032, United States
  • Investigational Site Number-1002
    Houston, Texas 77030, United States
  • Investigational Site Number-1001
    San Antonio, Texas 78229, United States
  • Investigational Site Number-7002
    Buenos Aires, Argentina
  • Investigational Site Number-2004
    New South Whales, Australia
  • Investigational Site Number-2001
    Perth, Australia
  • Investigational Site Number-2002
    Victoria, Australia
  • Investigational Site Number-2003
    Victoria, Australia
  • Investigational Site Number- 6001
    Santiago, Chile
  • Investigational Site Number-6002
    Santiago, Chile
  • Investigational Site Number-4002
    Singapore, Singapore
  • Investigational Site-4001
    Singapore, Singapore
  • Investigational Site Number-5001
    Barcelona, Spain
  • Investigational Site Number-5006
    Barcelona, Spain
  • Investigational Site Number-5007
    Barcelona, Spain
  • Investigational Site Number-5002
    Madrid, Spain
  • Investigational Site Number-5003
    Madrid, Spain
  • Investigational Site Number-5004
    Madrid, Spain
  • Investigational Site Number-5005
    Madrid, Spain
  • Investigational Site Number-5105
    Madrid, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Dec 2025, 77 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2019
First posted
Jul 5, 2019
StartActual
Jun 20, 2019
Primary completionActual
Dec 2, 2025
CompletionActual
Dec 2, 2025
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04009681
Responsible party
Sponsor
First posted
Jul 5, 2019
Start date
Jun 20, 2019
Primary completion
Dec 2, 2025
Completion
Dec 2, 2025
Last update
Dec 15, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegenzileukin

Start the discussion